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Background: Survival is poorer in elderly patients with head and neck squamous cell carcinomas [HNSCCs] than in
younger patients. Possible explanations include a contribution of co-morbidities to mortality, frequent refusal of standard
therapy, and the use of suboptimal treatments due to concern about toxicities. The Comprehensive Geriatric Assessment
[CGA] is a multidimensional assessment of general health that can help to customise treatment and follow-up plans. The
CGA has been proven effective in several health settings but has not been evaluated in randomised studies of patients
with cancer. Our aim here was to assess the impact of the CGA on overall survival, function, and nutritional status of
elderly patients with HNSCC.
Methods/design: EGeSOR is an open-label, multicentre, randomised, controlled, parallel-group trial in patients
aged 70 years or older and receiving standard care for HNSCC. The intervention includes four components: the
CGA conducted by a geriatrician before cancer treatment, participation of the same geriatrician in cancer treatment
selection, a standardised geriatric therapeutic intervention designed by the same geriatrician; and geriatric follow-up for
24 months. The primary endpoint, assessed after 6 months, is a composite criterion including death, functional
impairment [Activities of Daily Living score decrease ≥2], and weight loss ≥10%. Secondary endpoints include
progression-free survival, unscheduled admissions, quality of life, treatment toxicities, costs, and completion of the
planned cancer treatment. A centralised online system is used to perform 1:1 randomisation with a minimisation
algorithm for centre, age, T and N stages, and tumour site [oral, oropharyngeal, hypopharyngeal, or laryngeal]. The
estimated sample size is 704 patients, who are being recruited by 14 centres in 9 French cities.
Discussion: EGeSOR is the first randomised trial of the CGA in elderly cancer patients. We expect the CGA to have
direct clinical benefits on the management of elderly patients with HNSCC. If this expectation is fulfilled, the trial
may lead to modifications of the management model for elderly patients with cancer.
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Head and neck cancers are the sixth most common cancer
in the world according to 2006 European Cancer Observa-
tory data [1]. In parallel with the rise in life expectancy,
the number of elderly patients with head and neck squa-
mous cell carcinomas [HNSCCs] is increasing, especially
in women [2,3]. Overall survival [OS] in patients with
HNSCCs has been estimated at about 50% after 5 years,
with large variations across tumour sites [4-6]. Two studies
suggest lower 5-year OS rates in patients aged 75 or over
than in younger patients [7,8]. Possible explanations to this
difference may include a contribution of co-morbidities
to mortality [7,9], greater patient reluctance to undergo full
treatment regimens, and physician choice of suboptimal
treatments due to concern about toxicities [10]. Co-
morbidities become increasingly prevalent with advancing
age and are associated with treatment-related side effects
and poorer outcomes [9,11-13]. Although studies support
the use of similar cancer treatments in older and younger
patients [14,15], a thorough pre-treatment evaluation is
deemed crucial, most notably in elderly patients [16-18].
The Comprehensive Geriatric Assessment [CGA] was
developed by geriatricians as a ‘multidimensional inter-
disciplinary diagnostic process focussed on determining
a frail older person’s medical, psychological, and func-
tional ability in order to develop a coordinated and inte-
grated plan for treatment and long-term follow-up’ [19].
The CGA relies on validated geriatric scales or tests to
draw a detailed picture of the patient’s health status,
which can then serve to develop an individualised geriatric
intervention plan. The CGA is therefore both a diagnostic
and a therapeutic tool. It is designed to ensure that all
problems are identified, quantified, and managed appro-
priately. A meta-analysis showed that the CGA, combined
with multidisciplinary interventions, improved survival
and function and decreased the need for admission and
institutionalisation in elderly patients with non-malignant
diseases [20]. Over the past decade, the CGA has been
suggested for elderly patients with cancer and recom-
mended by the International Geriatric Oncology Society
[SIOG] [21] as a means of optimising cancer treatment se-
lection, improving the chances of treatment completion,
increasing survival, and diminishing adverse outcomes
[22-24]. However, randomised trials of the CGA are
available only for non-malignant conditions: there is no
high-level evidence on the potential benefits of the
CGA in elderly patients with cancer.
We hypothesised that performing the CGA in elderly pa-
tients with HNSCC would improve treatment decision-
making by better evaluating the patient’s functional reserve,
a crucial factor in the ability to tolerate cancer treatments;
and would improve OS, function, and nutritional status by
ensuring optimal customisation of the treatments and
follow-up during surgery and/or radiotherapy and/orchemotherapy. Our objective was to evaluate the impact of
the CGA on OS, function, and nutritional status of elderly
patients with HNSCC.
Methods/design
Study design and setting
We are conducting an open-label, multicentre, parallel-
group, randomised, controlled trial in patients aged
70 years or older and receiving standard care for HNSCC.
One group receives a CGA-based multi-component inter-
vention and the other does not [Figure 1]. The primary
endpoint is a composite criterion to be assessed after
6 months. Other endpoints such as OS and disease-free
survival are assessed after 24 months. The patients are be-
ing recruited at 14 ENT/maxillo-facial surgery departments
in 13 hospitals located in 9 cities in France [Paris, Créteil,
Montfermeil, Villeneuve-Saint-Georges, Lille, Strasbourg,
Nancy, Nantes, and Suresnes]. The protocol was approved
by the appropriate ethics committee [CPP Ile-de-France I,
Paris, France, approval April, the 20 April 2013;13213]. The
trial is registered on ClinicalTrials.gov [NCT02025062].
Study population
Inclusion criteria are age ≥70 years; macroscopic diagnosis of
head and neck cancer [oral, oropharyngeal, hypopharyngeal,
or laryngeal] awaiting histological confirmation; coverage by
the French statutory health insurance system; and written in-
formed consent obtained from the patient. Non-inclusion
criteria are as follows: correctional facility inmate; legal
guardianship; psychological, familial, social, or geographic
conditions that might interfere with the conduct of the
study; personal history of head and neck cancer; and rare
tumour site [sinonasal or salivary gland]. To prevent selec-
tion bias limiting the general applicability of our findings,
we are including consecutive patients who meet the
eligibility criteria.
Study intervention
The study intervention has four components.
(a) CGA before cancer treatment initiation, performed
by a geriatrician [designated the ‘intervention
geriatrician’ hereafter];
(b) participation of the intervention geriatrician in
developing the cancer-treatment plan;
(c) standardised multidimensional geriatric therapeutic
programme designed by the intervention geriatrician;
and
(d) geriatric follow-up during cancer treatment and for
24 months after randomisation.
(a) CGA
The CGA is performed by the intervention geriatrician,
after randomisation and before the multidisciplinary
Screening: consecutive patients 70 years or older with head and neck cancer awaiting 
pathological confirmation
Informed consent and inclusion
Pan-endoscopy and CT scan or MRI for TN staging
1:1 randomisation with minimisation (on centre, age, tumour site, 
and T&N stages)
Intervention group:  
CGA+ standard ENT management
Primary composite endpoint at M6: death,  
functional status, and weight loss
Secondary endpoints at M6, M12, and M24
Not eligible or 
refused consent






Primary composite endpoint at M6: death,  
functional status, and weight loss
Secondary endpoints at M6, M12, and M24
Figure 1 EGeSOR flow chart.
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established. The CGA consists in a detailed medical,
psychological, and social assessment including a careful
medical history and physical examination. In accord-
ance with SIOG recommendations for elderly cancer
patients, seven domains are assessed routinely: func-
tional status, mobility and fall risk, nutritional status
[25], cognitive status, mood, co-morbidities and medica-
tions, and social environment. These domains are assessed
using validated tests, questionnaires, scores, and/or scalesTable 1 Primary and secondary endpoints in the EGeSOR tria
Endpoints Time assessed Description
Primary endpoint 6 months after randomisation Composite c
- death,
- at least 2-p
score versu
- at least 10%















- costs[Table 1]. Pain is also evaluated using a verbal numeric
scale. The CGA is performed by a senior geriatrician, in
some cases with help from a trained healthcare worker
[usually a nurse working in the oncology and/or geriatric
department].
(b) Geriatrician participation in development of the
cancer-treatment plan
The intervention geriatrician lists all identified problems
by order of priority and provides specific advice on thel
riterion including
oint decrease in the Activities of Daily Living (ADL)
s baseline
decrease in body weight versus baseline




ry hospital stay length
o home or nursing home
r treatment plan (surgery, chemotherapy, targeted therapies,
y, and/or supportive care, alone or combined)
ife assessed by EORTC QLQ-C30 and specific module for
eck cancer H&N35
toxicities and/or complications: chemotherapy toxicities according to
n Common Terminology Criteria for Adverse Events (CTCAE version 4.02)
tment feasibility
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http://www.biomedcentral.com/1471-2407/14/427treatment goal [curative or palliative] and modalities [sur-
gery, radiotherapy, chemotherapy, targeted therapy, and
supportive care, used sequentially or simultaneously] in a
written report given to the ENT physicians in charge of
cancer treatment. The intervention geriatrician then partici-
pates in the multidisciplinary meeting held to determine
the cancer-treatment plan [23].(c) A standardised multidimensional geriatric therapeutic
programme
A geriatric therapeutic programme is implemented at
baseline and during follow-up. The intervention geriatri-
cian designs this programme based on the CGA findings,
in cooperation with the ENT physicians, other ENT
healthcare staff, and outpatient healthcare professionals.
The programme has four components: optimising the
management of problems detected in the seven health
domains evaluated during the CGA, a medication review,
patient education on co-morbidity self-management, and
information on cancer treatments [26]. These components
are standardised and compliant with the most recent rec-
ommendations issued by the French National Authority
for Health [HAS], French Society for Gerontology and
Geriatrics, and French Society for Cardiology, as appropri-
ate [Table 2]. Regarding co-morbidities, the geriatric inter-
vention focuses on the five most common conditions
present in elderly patients with head and neck cancer:
chronic atrial fibrillation, chronic heart failure, diabetes,
coronary artery disease, and hypertension. Corrective
measures are taken as required. A geriatrician specialised
in geriatric oncology [PC] is available by phone or e-mail
for discussion with the intervention geriatrician. Careful
attention is directed to complaints of pain. Analgesic med-
ications are adjusted as needed and patients referred to a
pain clinic if appropriate.(d) Geriatric follow-up
The standardised geriatric follow-up provided by the
intervention geriatrician, consists in a brief assessment of
nutrition, mood, pain, functional status, the five above-
listed co-morbidities, self-perceived health status, medica-
tion use, and implementation of the multidimensional
geriatric therapeutic programme. The results of this stan-
dardised follow-up are used to make recommendations to
the ENT physician, oncologist, radiotherapist and general
practitioner.
Follow-up includes closely spaced physical examinations
for 1 to 6 months depending on the treatment modalities;
Figure 2 is an example for a surgically managed patient.
After completion of the initial cancer treatment, the inter-
vention geriatrician or nurse phones the patient every
3 months during the first 2 years after randomisation. If
problems are identified during any of these phone calls, anappointment for a visit with the intervention geriatrician is
scheduled.
During follow-up, the patient has access to the resources
provided by the local geriatric network: geriatric rehabilita-
tion unit, geriatric day hospital, geriatric and/or oncology
community centre, geriatric nursing home intervention,
and home nursing care.
Intervention geriatrician
The intervention geriatricians involved in the study are
senior geriatricians with a mean of 3 years of post-
degree experience in geriatrics. Before inclusion of the
first patient in their centre, the EGeSOR coordination
team composed of four geriatricians [EP, PC, ML, MB] pro-
vided the intervention geriatricians with a half day of train-
ing in the EGeSOR intervention and in the specific features
of HNSCC.
Endpoints
Table 2 shows the primary and secondary endpoints.
The primary endpoint is a composite criterion evaluated
6 months after randomisation and including death, an
at least 2-point decrease in the Activities of Daily Living
[ADL] score [27] versus baseline, and at least 10% weight
loss versus baseline. A clinical research assistant blinded
to the randomisation arm uses a standardised measure-
ment guide to adjudicate the ADL score and weight.
Weight is measured to the nearest 0.1 Kg using an elec-
tronic scale [Seca Model 876, Birmingham, United
Kingdom]. Our decision to include functional and nutri-
tional measures into the primary endpoint rests both on
sound evidence that these measures influence treatment
feasibility, patient survival, and quality of life; and on the
potential for appropriate management to reverse func-
tional impairments and weight loss.
Random assignment
After including each patient and obtaining the panendo-
scopy and computed tomography or magnetic resonance
imaging findings to allow TN staging, the ENT physician
or clinical research assistant records the centre, patient age,
tumour site, and TN stage into an online central random-
isation system [RandoWeb, Paris, France] [28]. The soft-
ware automatically checks the data for completeness and
consistency then allocates the patient to the intervention
group or control group. All patients receive standard
HNSCC therapy. The randomisation system applies a mini-
misation programme to balance the two groups regarding
centre, age [<or ≥80 years], T stage [<or ≥T2], N stage
[<or ≥N2], and tumour site [oral, oropharyngeal, hypophar-
yngeal, or laryngeal]. Minimisation randomly allocates the
first patient to a group then allocates each subsequent pa-
tient to the group that produces the smallest difference be-
tween treatment groups regarding the five above-listed
Table 2 Standardised multidimensional geriatric therapeutic programme in the intervention arm of the EGeSOR trial;
ADL, Activities of Daily Living score; IADL, Instrumental Activities of Daily Living score; MNA, Mini-Nutritional Assessment;
BMI, body mass index; MMSE, Mini-Mental State Examination; GDS, Geriatric Depression Scale; CIRS-G, Cumulative Illness
Rating Scale-Geriatrics
Domains Assessment tools – thresholds for interventions Standardised responses
Functional status ADL ≤5 Social services notification
AND/OR Home care
IADL≤ 7 Access to geriatric network
Mobility/fall risk Falls during the last 6 months Walking and/or standing-balance rehabilitation (20 sessions)
AND/OR AND
One-leg standing test <5 seconds Fall management(1)
AND/OR
Timed get-up-and-go test >20 seconds
Nutritional status MNA≤ 17 Nutritional care according to severity of malnutrition
and swallowing disorders(2)
AND/OR - Dietician visits
Weight loss ≥5% in the last 3 months - High-energy and high-protein diet
AND/OR - Nutritional supplements
Weight loss ≥10% in the last 6 months - Enteral nutrition
AND/OR - Monitoring of local/regional treatment prescribed
by the ENT physician, including oral care(3)
BMI < 21 Kg/m2 - Access to geriatric network
- Education on disease self-management
Cognitive status MMSE≤ 23 - Evaluation for causes of delirium
and correction of predisposing factors(4)
- Neuropsychological assessment with evaluation of memory
- Access to geriatric network
Depression GDS-15≥ 6 - Antidepressant treatment(5)
- Follow-up by a psychologist
- Psychiatrist visit, depending on severity
- Access to geriatric network
Co-morbidities CIRS-G: - Medication review and medication regimen optimisation(6)
at least one co-morbidity (other than the HNSCC) grade ≥3 - Access to geriatric network
AND/OR - Education on disease self-management:
Number of drugs ≥5/day - Diabetes in the elderly: facts and management(7) -
Atrial fibrillation: facts and management(8)
Focus on five diseases: chronic atrial fibrillation,
chronic systolic heart disease, diabetes,
coronary artery disease, hypertension
- Management of coronary heart disease in older adults(9)
- Diagnosis and management of chronic systolic heart disease
(1)Assessment and prevention of falls in older people – Practice guidelines. Online in April 2009.
(2)Malnutrition in the elderly - Nutritional support strategy. Practice guidelines. Online in June 2007.
Physiotherapy - Preserving motor function in frail elderly people living at home Practice guidelines. Online in April 2005.
(3)Upper aerodigestive cancers - Practice guidelines ALD n°30. Online in November 2009.
(4)Alzheimer's disease and related conditions - Diagnosis and treatment: Practice guidelines. Online in December 2011.
(5)A workshop on psychotropic drug prescriptions in the elderly. Online in October 2007.
(6)Improving the primary care prescription of hypnotic and anxiolytic drugs in the French elderly. Online in March 2009.
(6)Improving drug prescription in older persons. Online in November 2012.
(7)Guidelines for the management and care of diabetes in the elderly. Online in January 2011.
(8)Guidelines for the management of patients with atrial fibrillation. Online in July 2007.
All guidelines available at http://www.has-sante.fr/portail/jcms/fc_1249588/fr/accueil-2012/ Last accessed 27 December 2013.
Expert consensus of the French Society for Geriatrics and Gerontology and French Society for Cardiology on the management of atrial fibrillation in elderly people
(2013), at http://www.sfcardio.fr/.
(9) Consensus of the French Society for Gerontology and Geriatrics and French Society for Cardiology for the management of coronary heart disease, at www.sfcardio.fr.
(10) Therapeutic education in patients with chronic heart failure : proposal for multiprofessional structured programme by a French task force under the auspices
of the French Society of Cardiology at www.sfcardio.fr.













* * * *
*Data to be collected by the clinical research assistant independently from the ENT healthcare 
professionals and geriatrician in charge of the patient
Primary composite 
endpoint:
vital status, ADL, and 
weight*
Figure 2 Follow-up over the first 6 months (M) for patients treated with surgery alone in the EGeSOR study.
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can, in theory, lead to alternation of treatment allocation,
the algorithm also incorporates 30% of random allocation.
This helps to ensure concealment.
Sample size estimation
We hypothesised that the intervention would result in an
at least 10% absolute decrease in the primary endpoint,
and we assumed that 30% of controls would achieve the
primary endpoint. With a 5% two-sided alpha risk and
80% power, 640 patients would be needed [320 in each
group]. We assumed that 10% of patients would be lost to
follow-up before study completion or would not have data
on the primary endpoint. Therefore, we plan to include
704 patients in all.
Statistical analysis
Data will be analysed according to CONSORT guidelines
[30]. The descriptive analysis will compare the two rando-
mised groups in terms of general characteristics, demo-
graphics, co-morbidities, risk factors, and baseline HNSCC
characteristics. Only descriptive statistics will be used at this
stage. Quantitative variables will be described as mean [±1
standard deviation (SD)] or median [25-75th percentiles]
according to their distribution and qualitative variables as
numbers [%].
A flow diagram will be created according to CONSORT
guidelines. The primary endpoint will be analysed usingthe intent-to-treat approach, with all patients kept in the
group to which they were assigned by the randomisation
system. We will compare the proportions of patients
achieving the primary endpoint in the two groups using
Pearson’s chi-square test, and we will assess effect size by
computing the relative risk with its 95% confidence inter-
val [95% CI] and the absolute difference between groups.
This analysis will be adjusted for any baseline patient char-
acteristics that are imbalanced between the two groups.
For between-group comparisons of secondary endpoints,
we will use the same method as for the primary endpoint.
Variables measured serially during follow-up [func-
tional status, depressive mood, weight, pain, and quality
of life] will be analysed using mixed models to take into
account the repetition of the measures. Quality-of-life
data will be analysed using QLQ-C30 and H&N35
[8,31,32]. Subgroup analyses will be conducted according to
age group [<or ≥80 years], tumour site, and tumour stage.
Costs
We will estimate the cost of our four-component inter-
vention, compare the costs of the intervention and control
management strategies, and compute an incremental cost-
effectiveness ratio. Costs will be estimated from the
perspective of the French healthcare system, from ran-
domisation to death or end of follow-up. Only direct costs
will be counted. In each patient, all resources used will be
recorded prospectively, using the same methodology in
Brugel et al. BMC Cancer 2014, 14:427 Page 7 of 9
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visits, medical interventions, and investigations], treatments
[surgery, cytotoxic or targeted chemotherapy, radiotherapy,
and supportive treatments (including recombinant human
erythropoietin, anti-emetics, and colony-stimulating fac-
tors)], nutritional care [nutritional supplements and enteral
nutrition], acute admissions for any reason, residence in a
nursing home or rehabilitation unit, community care [phys-
ician visits and investigations during follow- up, number of
physiotherapist sessions, number of home healthcare pro-
fessional visits, and care provided at skilled nursing facil-
ities]. The cost per resource unit will be taken from the cost
lists established by the French statutory healthcare system.
Differences in costs and differences in effectiveness on the
primary endpoint will be used to estimate the incremental
cost-effectiveness ratio. Costs will be reported as median
[25th-75th percentiles] and mean [SD] and compared using
the Wilcoxon-Mann–Whitney test and parametric tests.
Confidence intervals will be estimated by bootstrapping with
1000 re-samplings of the original dataset.
The significance level will be 5%. All tests will be two-
tailed. Data will be analysed using Stata Software [College
Station, TX, USA].
Discussion
The EGeSOR trial aims to demonstrate that a multidimen-
sional geriatric intervention based on an initial CGA,
when added to standard care for HNSCC in elderly pa-
tients, significantly improves a 6-month composite end-
point of survival, functional status, and weight. The full
picture of co-morbid conditions produced by the CGA
may improve cancer treatment selection. Many elderly in-
dividuals have potentially fatal co-morbidities, which both
compete with HNSCC as a cause of death and influence
the risk/benefit ratio of cancer treatments. Moreover, the
data on functional reserve provided by the CGA may help
to predict the patient’s ability to tolerate specific cancer
treatments. The personalised geriatric follow-up during
cancer treatment, including adjustment of the treatments
and management of the co-morbidities and iatrogenic
complications, may increase the likelihood of cancer-
treatment feasibility, improve quality of life, and decrease
unplanned admissions and hospital stay length. Finally,
the trial preparation phase strengthened the collaboration
between ENT physicians and geriatricians, and we expect
this beneficial effect to continue throughout the trial.
The study intervention consists of four components: the
CGA performed by the intervention geriatrician at baseline,
participation of the intervention geriatrician in developing
the cancer treatment plan, a standardised multidimensional
geriatric therapeutic programme, and geriatric follow-up
for 24 months. The first two components have been
proven to benefit treatment decisions [23,33-35]. A
Cochrane Collaboration meta-analysis showed that thelast two components improved survival and maintenance
at home in elderly patients with non-malignant diseases
[20]. The SIOG has recommended performing the CGA
in vulnerable elderly patients with cancer [21]. However,
no previous studies evaluated the impact of the CGA in
elderly patients with cancer.
The EGeSOR trial has several limitations. First, the CGA
is time consuming and requires extensive involvement of
geriatric teams, which may not be available in some cen-
tres. We visited each of the study centres to verify that the
number of geriatricians was sufficient, and we considered
reinforcing the geriatric team if necessary. Second, the pri-
mary endpoint is a composite criterion. However, demon-
strating superiority of the study intervention on a single
endpoint would have required such a large sample size as
to compromise feasibility of the trial. Third, contamination
bias may occur between the intervention and control
groups, as each ENT physician manages patients in both
groups. Conceivably, ENT physicians may apply knowledge
acquired by managing intervention patients to their control
patients, for instance by asking geriatricians for advice re-
garding vulnerable controls. Such contamination bias
would diminish the size of the effect of the intervention.
However, any contamination bias is probably limited, since
modifications potentially introduced by ENT physicians in
controls would have a very small effect compared to the
full four-component intervention. Nevertheless, we are re-
cording the number of times that advice from geriatricians
is provided for control patients. Our study had several
strengths. To our knowledge, it is the first randomised con-
trolled trial evaluating the efficacy of the CGA in elderly
cancer patients. We decreased the risk of selection bias by
using randomisation with minimisation, the risk of evalu-
ation bias by selecting objective clinical endpoints and
using independent adjudication, and the risk of confu-
sion bias by using randomisation with minimisation
and a pre-specified multivariate analysis to correct for
any baseline between-group imbalances. Finally, the
standardised multidimensional geriatric therapeutic
programme was designed in accordance with the most
recent clinical recommendations and relied on vali-
dated international measurement tools.Conclusion
The CGA has been proven in several randomised trials
and meta-analyses in the general geriatric population to
improve survival, institutionalisation rates, and functional
status. The EGeSOR trial is the first randomised trial of
the CGA in elderly cancer patients. We expect to demon-
strate a direct clinical benefit of the CGA on outcomes of
elderly patients with HNSCC. If such a benefit is found,
the results of the EGeSOR trial may change the healthcare
management model for elderly patients with cancer.
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